Cargando…
Potential Therapeutic Targets in Uterine Sarcomas
Uterine sarcomas are rare tumors accounting for 3,4% of all uterine cancers. Even after radical hysterectomy, most patients relapse or present with distant metastases. The very limited clinical benefit of adjuvant cytotoxic treatments is reflected by high mortality rates, emphasizing the need for ne...
Autores principales: | Cuppens, Tine, Tuyaerts, Sandra, Amant, Frédéric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632006/ https://www.ncbi.nlm.nih.gov/pubmed/26576131 http://dx.doi.org/10.1155/2015/243298 |
Ejemplares similares
-
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
por: Tuyaerts, Sandra, et al.
Publicado: (2018) -
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
por: Vanderstraeten, Anke, et al.
Publicado: (2014) -
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
por: De Wispelaere, Wout, et al.
Publicado: (2021) -
In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer
por: Vanderstraeten, Anke, et al.
Publicado: (2016) -
Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
por: Baiden-Amissah, Regina Esi Mensimah, et al.
Publicado: (2021)